

## **Q-Med AB: Invitation to interim report conference call January-September 2008**

**Time:** Friday, October 24, 2008 at 10.00 a.m. CET.

**To join the conference:**

Swedish dial in number: + 46 (0)8 505 201 10

UK dial in number: +44 (0)20 7162 0025

**Q-Med participants:**

Bengt Ågerup, President and CEO

Alexander Kotsinas, Vice President and CFO

Madelene Sandgren, Director Investor Relations and Corporate Communications

The press release for Q-Med AB's interim report will be released approximately 08.00 a.m on October 24, 2008.

The slide presentation will be available at:

[www.q-med.com](http://www.q-med.com) / Investors / Presentations

A recorded version of the presentation will be available for seven working days on tel: +44 (0)20 7031 4064, access code: 81 34 11.

**Queries should be addressed to:**

Madelene Sandgren, Director Investor Relations and Corporate Communications,

Tel: + 46 (0)70 974 90 15

---

**Q-Med AB** is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, **NASHA™**, for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: **Restylane®** for filling lines and folds, contouring and creating volume in the face, **Macrolane™** for body contouring, **Durolane™** for the treatment of osteoarthritis of the hip and knee joints, **Deflux®** for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and **Solesta™** for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has just over 700 coworkers, with close to 500 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in Stockholm.

---